Background
The numbers of children born to mothers living with HIV-1 are on the rise. While antiretroviral drugs (ARVs) prevent mother-to-fetus HIV-1 transmission, risks of adverse events on fetal neurodevelopment associated with in utero ARV exposure remain. HIV-1-exposed uninfected (HEU) children exposed in utero to ARVs are known to have poor neurodevelopment across multiple domains including cognitive, motor, language, or socio-emotional functions. An understanding of gestational ARV-associated developmental neurotoxicity is limited due to the time required for longitudinal assessment of functional neurodevelopment post-birth. With more than a million HEU children born each year, identifying underlying mechanisms of in utero ARV-linked adverse neurodevelopment and developing intervention strategies is timely. Thus, we posit that novel cerebral organoids can reflect ARV effects on fetal neurodevelopment.
Methods
Human induced pluripotent stem cells (iPSCs) derived from fibroblasts (Male; Age 30) were utilized to develop cerebral organoids. Cerebral organoid cultures were treated with therapeutic or supratherapeutic equivalent dolutegravir (DTG) concentration (10 or 25 µM) or vehicle (control). Treatment was initiated with the introduction of differentiation media. Cerebral organoids were evaluated on day 20 and 60 of treatment.
Results
Presence of ectodermal progenitor cells (SOX2 PAX6), mesodermal progenitor cells (brachyury), intermediate progenitor cells (TBR2), early and mature neurons (TUJ1, and MAP2), microglia (IBA-1), astrocytes (GFAP), and oligodendrocytes (OLIG2) were successfully confirmed in all organoids. A significant decrease in maturation of cerebral organoids was observed at both concentrations of DTG compared to the control. On day 20, the average perimeter of organoids was 1480.21 µm for control and 1080.58 µm and 864.09 µm for 10 µM and 25 µM DTG groups, respectively. On day 60, the average perimeter of organoids was 1820.71 µm for control, and 760.78 µm and 737.69 µm for 10 µM and 25 µM DTG groups, respectively. The slower maturation of organoids in DTG groups at both time points indicated lack of growth recovery at later stages of development.
Conclusions
These proof-of-concept data demonstrate that in utero DTG exposure may cause reduction in neural stem cell expansion, neurogenesis, and neuronal differentiation. Novel cerebral organoids may allow studying complex co-morbid effects of HIV-1, ARVs, and substance use on fetal neurodevelopmental processes.
Table or Figure
